BUSINESS

Santen Curbs Cosopt Mini Shipments after Quake, Nitto Medic to Re-Supply All Products

January 12, 2024

Santen Pharmaceutical on January 11 started restricting shipments for its glaucoma and ocular hypertension eye drops Cosopt Mini (dorzolamide + timolol) as its main plant was damaged by the New Year’s Day earthquake in central Japan.

The ophthalmology powerhouse suffered the impact of the disaster at its Noto Plant in Ishikawa Prefecture, which accounts for as much as three-fourths of the company’s annual production volume for in-house products. Some of the factory buildings and equipment sustained damages, according to the company.

The timeline towards the product’s normal supply is unclear at this time. Other than Cosopt Mini, the drug maker has a certain amount of inventories at hand and thus expects to continue normal supplies for other products.

On the same day, Nitto Medic, an eye drug specialist headquartered in Toyama, provided a timeline for the re-supply of all un-refrigerated drugs now under shipment suspensions.

On January 9, the company had announced that it was suspending shipments for all products excluding refrigerated medicines. Subject to the shipment suspension were 69 products, predominantly eye drops. The quake crippled its automated warehouse, making it impossible to take out the stored products, it had explained.

In the latest update, Nitto Medic said it will gradually start taking orders from January 12 and resuming supplies, beginning from January 16. However, eight products would be under restricted shipments upon the re-supply, it said.

Related Article

BUSINESS

By Philip Carrigan

Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…

By Ken Yoshino

On March 5, Japan unveiled new NHI prices for the FY2024 drug price revision. A Jiho survey found that Tsumura, a specialist in Japanese Kampo herbal medicines, received an astonishing raise of over 24% in its drug prices on a…

A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…

By Izuru Ando

Generic manufacturers in Japan will be required to disclose supply-related information from this June under a new company indicator rule…

The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…

By Yoshinori Sagehashi

The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…

A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…

Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…

Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…